MA39186A1 - Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose - Google Patents
Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmanioseInfo
- Publication number
- MA39186A1 MA39186A1 MA39186A MA39186A MA39186A1 MA 39186 A1 MA39186 A1 MA 39186A1 MA 39186 A MA39186 A MA 39186A MA 39186 A MA39186 A MA 39186A MA 39186 A1 MA39186 A1 MA 39186A1
- Authority
- MA
- Morocco
- Prior art keywords
- leishmaniasis
- protozoan
- triazolo
- derivatives
- treatment
- Prior art date
Links
- 208000004554 Leishmaniasis Diseases 0.000 title abstract 2
- 208000030852 Parasitic disease Diseases 0.000 title 1
- 229940079156 Proteasome inhibitor Drugs 0.000 title 1
- SRNKZYRMFBGSGE-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CN=C21 SRNKZYRMFBGSGE-UHFFFAOYSA-N 0.000 title 1
- 239000003207 proteasome inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010001935 American trypanosomiasis Diseases 0.000 abstract 1
- 208000024699 Chagas disease Diseases 0.000 abstract 1
- 241000223109 Trypanosoma cruzi Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000002311 trypanosomiasis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (a), ou un sel, un tautomère ou un stéréoisomère pharmaceutiquement acceptable de ceux-ci, les variables étant telles que définies dans la description. La présente invention concerne en outre des compositions pharmaceutiques comprenant de tels composés et des procédés d'utilisation de ces composés pour traiter, prévenir, inhiber, améliorer ou éradiquer la pathologie et/ou la symptomatologie d'une maladie provoquée par un parasite, comme la leishmaniose, la trypanosomiase humaine africaine et la maladie de chagas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361918089P | 2013-12-19 | 2013-12-19 | |
PCT/US2014/071077 WO2015095477A1 (fr) | 2013-12-19 | 2014-12-18 | Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39186A1 true MA39186A1 (fr) | 2017-11-30 |
Family
ID=52302387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39186A MA39186A1 (fr) | 2013-12-19 | 2014-12-18 | Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose |
Country Status (41)
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016269626B2 (en) * | 2015-05-29 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents |
EP3331885B1 (fr) * | 2015-08-07 | 2020-12-23 | GlaxoSmithKline Intellectual Property Development Limited | Composés |
WO2017127627A1 (fr) | 2016-01-21 | 2017-07-27 | The University Of North Carolina At Chapel Hill | Composés pour traiter les trypanosomes et les pathogènes neurologiques et leurs utilisations |
CA3057377A1 (fr) | 2017-03-27 | 2018-10-04 | Hydro-Quebec | Sels destines a etre utilises dans des compositions d'electrolyte ou en tant qu'additifs d'electrode |
JOP20190278A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
EA039324B1 (ru) * | 2017-11-06 | 2022-01-13 | Новартис Аг | 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний |
TW202028208A (zh) | 2018-10-09 | 2020-08-01 | 瑞士商諾華公司 | N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]三唑并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4038396A (en) | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
DE3130633A1 (de) * | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
DE3224512A1 (de) | 1982-07-01 | 1984-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
FR2652085A1 (fr) | 1989-09-20 | 1991-03-22 | Science Organisation | Nouveau procede de synthese de derives d'oxazolopyridines. |
DE4129603A1 (de) | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
JPH0643588A (ja) * | 1992-07-27 | 1994-02-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
DE4304650A1 (de) | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
JP3735741B2 (ja) * | 1995-11-24 | 2006-01-18 | 株式会社大塚製薬工場 | 縮環ピリミジン誘導体 |
WO1998006703A1 (fr) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | Derives 2-phenyle benzimidazole en tant qu'antagonistes de mcp-1 |
WO1998010779A1 (fr) * | 1996-09-13 | 1998-03-19 | New York University | Methode pour traiter des maladies parasitaires avec des inhibiteurs de proteasome |
CA2402516A1 (fr) | 2000-03-20 | 2001-09-27 | Roopa Rai | Inhibiteurs de la protease exempte d'amidine |
WO2001096336A2 (fr) | 2000-06-14 | 2001-12-20 | Warner-Lambert Company | Heterocyles bicycliques fondus -6,5 |
AU2002216649A1 (en) | 2000-10-31 | 2002-05-15 | Lynn Bonham | Benzoxazole lpaat- beta inhibitors and uses thereof |
WO2002038153A1 (fr) | 2000-11-09 | 2002-05-16 | Biovitrum Ab | Nouvelle utilisation de derives de 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine |
WO2002044126A2 (fr) | 2000-11-28 | 2002-06-06 | Guilford Pharmaceuticals Inc. | Composes de liaison de cyclophiline carbocyclique bisubstituee et leur utilisation |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
CN1638765A (zh) | 2001-07-27 | 2005-07-13 | 柯里斯公司 | Hedgehog信号转导途径介质、其相关组合物以及应用 |
US7488598B2 (en) | 2001-10-26 | 2009-02-10 | Cornell Center For Technology Enterprise And Commercialization | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
CN100338040C (zh) | 2001-11-16 | 2007-09-19 | 日本化学医药株式会社 | 黄嘌呤氧化酶抑制化合物 |
AU2002349477A1 (en) | 2001-11-26 | 2003-06-10 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
WO2004078163A2 (fr) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
ES2298798T3 (es) * | 2003-07-30 | 2008-05-16 | Laboratorios S.A.L.V.A.T., S.A. | Imidazopirimidinas sustituidas para la prevencion y el tratamiento del cancer. |
JP2007501618A (ja) | 2003-08-08 | 2007-02-01 | アバニール・ファーマシューティカルズ | タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法 |
MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
WO2005030206A1 (fr) | 2003-09-24 | 2005-04-07 | Imclone Systems Incorporated | Derives d'aryl-1,3-azole et procedes permettant d'inhiber l'activite de l'heparanase |
AU2005220882A1 (en) | 2004-03-08 | 2005-09-22 | Georgia State University Research Foundation, Inc | Novel dicationic imidazo(1,2-a)pyridines and 5,6,7,8-tetrahydro-imidazo(1,2a)pyridines as antiprotozoal agents |
CA2589779A1 (fr) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques |
WO2006066914A2 (fr) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques |
WO2006101456A1 (fr) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Composes d'hydraxamate bicycliques contenant des heterocycles utiles en tant qu'inhibiteurs de l'histone desacetylase (hdac) |
ATE499372T1 (de) | 2005-07-29 | 2011-03-15 | Hoffmann La Roche | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel |
US7776878B2 (en) | 2005-08-01 | 2010-08-17 | Hoffmann-La Roche Inc. | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
WO2007019345A1 (fr) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Dérivés de l’imidazopyridine en tant qu’agents modulant la sirtuine |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
US7438916B2 (en) | 2005-10-14 | 2008-10-21 | Virginia Tech Intellectual Properties, Inc. | Therapeutic target for protozoal diseases |
EP2023919A4 (fr) | 2006-05-08 | 2010-12-22 | Molecular Neuroimaging Llc | Composés et sondes amyloïdes de ceux-ci pour des utilisations thérapeutiques et en imagerie |
PL2054405T3 (pl) | 2006-07-11 | 2014-03-31 | Dae Woong Pharma | Nowe pochodne biarylobenzimidazolu i zawierająca je kompozycja farmaceutyczna |
PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
PE20080888A1 (es) | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
WO2008100376A2 (fr) | 2007-02-15 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Variants de troncature de sirt1 et procédés d'utilisation de ceux-ci |
CA2681813A1 (fr) | 2007-03-27 | 2009-01-08 | Paratek Pharmaceuticals, Inc. | Composes modulant le facteur de transcription et leurs procedes d'utilisation |
CA2682676A1 (fr) | 2007-04-19 | 2008-10-30 | Novartis Ag | Composes organiques |
EP2170337A4 (fr) | 2007-06-28 | 2013-12-18 | Abbvie Inc | Nouvelles triazolopyridazines |
TWI444379B (zh) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Raf激酶抑制劑之化合物 |
TW200932872A (en) | 2007-10-17 | 2009-08-01 | Cheil Ind Inc | Novel compound for organic photoelectric device and organic photoelectric device including the same |
RU2364597C1 (ru) | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
WO2009112445A1 (fr) | 2008-03-10 | 2009-09-17 | Novartis Ag | Procédé d’accroissement de phosphatidyl-choline des cellules par l’inhibition de la dgat1 |
US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
KR101354763B1 (ko) | 2008-08-25 | 2014-01-22 | 아이알엠 엘엘씨 | 헷지호그 경로 조절제 |
US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
UY32776A (es) * | 2009-07-09 | 2011-02-28 | Irm Llc | Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación. |
WO2011027249A2 (fr) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Dérivés de benzimidazole |
BR112012007179B8 (pt) * | 2009-09-29 | 2021-05-25 | Univ Texas | composto inibidor da di-hidro-orotato desidrogenase, e, formulação farmacêutica |
CA2787784A1 (fr) * | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc. | Petites molecules pour la modulation de mcl-1 et procedes de modulation de la mort cellulaire, la division cellulaire, la differenciation cellulaire et procedes de traitement de troubles |
CA2837818A1 (fr) | 2010-06-03 | 2011-12-08 | The Regents Of The University Of California | Procedes et compositions pour le traitement d'un sujet pour une lesion du systeme nerveux central (snc) |
TWI617559B (zh) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | 2-芳基咪唑并[1,2-b]嗒.2-苯基咪唑并[1,2-a]吡啶,和2-苯基咪唑并[1,2-a]吡衍生物 |
US9206164B2 (en) | 2011-03-25 | 2015-12-08 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
WO2013009827A1 (fr) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Méthodes de traitement |
GB201114051D0 (en) | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
UA123760C2 (uk) | 2011-11-11 | 2021-06-02 | Гіліад Аполло, Ллс | Сполука (варіанти) та композиція, що містить сполуку |
WO2013078254A1 (fr) | 2011-11-22 | 2013-05-30 | Array Biopharma Inc. | Dérivés hétéroaryles bicycliques en tant qu'inhibiteurs de kinase |
EP2822948B1 (fr) * | 2012-03-07 | 2016-04-06 | Merck Patent GmbH | Dérivés de triazolopyrazine |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
TW201406736A (zh) | 2012-06-28 | 2014-02-16 | Fujifilm Corp | 新穎的醯胺衍生物或其鹽 |
CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
EP2888251B1 (fr) | 2012-08-21 | 2019-04-24 | Peter MacCallum Cancer Institute | Composés de benzènesulfonamide inhibiteurs de la perforine, leur préparation et leurs utilisations |
WO2014151729A1 (fr) | 2013-03-15 | 2014-09-25 | Irm Llc | Composés et compositions pour le traitement de maladies parasitaires |
US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
UY35400A (es) * | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
-
2014
- 2014-12-18 MA MA39186A patent/MA39186A1/fr unknown
- 2014-12-18 LT LTEP14825046.7T patent/LT3083627T/lt unknown
- 2014-12-18 SI SI201430990T patent/SI3083627T1/sl unknown
- 2014-12-18 BR BR112016014004-4A patent/BR112016014004B1/pt active IP Right Grant
- 2014-12-18 PE PE2016000831A patent/PE20160865A1/es active IP Right Grant
- 2014-12-18 RS RS20181477A patent/RS58053B1/sr unknown
- 2014-12-18 PL PL14825046T patent/PL3083627T3/pl unknown
- 2014-12-18 EP EP14825046.7A patent/EP3083627B1/fr active Active
- 2014-12-18 CN CN201480075574.3A patent/CN106029666B/zh active Active
- 2014-12-18 US US14/574,775 patent/US9303034B2/en active Active
- 2014-12-18 DK DK14825046.7T patent/DK3083627T3/da active
- 2014-12-18 CA CA2932870A patent/CA2932870C/fr active Active
- 2014-12-18 MX MX2016008079A patent/MX368072B/es active IP Right Grant
- 2014-12-18 HU HUE14825046A patent/HUE040254T2/hu unknown
- 2014-12-18 TN TN2016000253A patent/TN2016000253A1/en unknown
- 2014-12-18 PT PT14825046T patent/PT3083627T/pt unknown
- 2014-12-18 AP AP2016009329A patent/AP2016009329A0/en unknown
- 2014-12-18 AU AU2014364565A patent/AU2014364565B2/en active Active
- 2014-12-18 NZ NZ721650A patent/NZ721650A/en unknown
- 2014-12-18 MY MYPI2016702061A patent/MY175865A/en unknown
- 2014-12-18 UA UAA201607112A patent/UA117046C2/uk unknown
- 2014-12-18 TW TW103144389A patent/TWI674263B/zh active
- 2014-12-18 KR KR1020167019388A patent/KR102354082B1/ko active IP Right Grant
- 2014-12-18 CR CR20160334A patent/CR20160334A/es unknown
- 2014-12-18 CU CU2016000090A patent/CU24379B1/es unknown
- 2014-12-18 EA EA201691271A patent/EA030823B1/ru not_active IP Right Cessation
- 2014-12-18 JP JP2016541014A patent/JP6392352B2/ja active Active
- 2014-12-18 ES ES14825046T patent/ES2701087T3/es active Active
- 2014-12-18 SG SG11201604618TA patent/SG11201604618TA/en unknown
- 2014-12-18 WO PCT/US2014/071077 patent/WO2015095477A1/fr active Application Filing
- 2014-12-19 UY UY0001035903A patent/UY35903A/es not_active Application Discontinuation
- 2014-12-19 AR ARP140104775A patent/AR098844A1/es unknown
-
2016
- 2016-02-23 US US15/051,446 patent/US9700559B2/en active Active
- 2016-06-05 IL IL246034A patent/IL246034B/en active IP Right Grant
- 2016-06-09 CL CL2016001421A patent/CL2016001421A1/es unknown
- 2016-06-16 SV SV2016005226A patent/SV2016005226A/es unknown
- 2016-06-17 GT GT201600131A patent/GT201600131A/es unknown
- 2016-06-17 PH PH12016501198A patent/PH12016501198A1/en unknown
- 2016-06-29 ZA ZA2016/04415A patent/ZA201604415B/en unknown
- 2016-08-16 EC ECIEPI201667921A patent/ECSP16067921A/es unknown
-
2017
- 2017-05-19 US US15/600,183 patent/US10085989B2/en active Active
-
2018
- 2018-08-29 US US16/116,418 patent/US10596175B2/en active Active
- 2018-11-30 HR HRP20182021TT patent/HRP20182021T1/hr unknown
- 2018-12-05 CY CY181101300T patent/CY1121060T1/el unknown
-
2020
- 2020-02-03 US US16/780,628 patent/US11123348B2/en active Active
-
2021
- 2021-08-10 US US17/398,852 patent/US20210369716A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39186A1 (fr) | Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose | |
MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
MA31419B1 (fr) | Derives de pyridine | |
MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
MA34342B1 (fr) | Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer | |
MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
MA38138A1 (fr) | Dérivés inédits de quinolone | |
MA34397B1 (fr) | Dérivés d'acide napht-2-ylacétique dans le traitement du sida | |
TNSN07022A1 (fr) | Derives de pyridine | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
MA34760B1 (fr) | Composés et leurs utilisation | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA35932B1 (fr) | Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
MA38009A1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
MA33979B1 (fr) | Piperazines en tant qu'agents antipaludiques | |
TN2014000371A1 (fr) | Dérivés macrocycliques pour le traitement de maladies prolifératives | |
MA37291A2 (fr) | Dérivés macrocycliques pour le traitement de maladies prolifératives |